in this issue
The cost of life: should it matter to doctors?
Breaking bad news in oncology: like a walk in the twilight?
The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?
Pulmonary toxicity from novel antineoplastic agents
An economic evaluation of Herceptin® in adjuvant setting: the Breast Cancer International Research Group 006 trial
Survival and prognostic factors in BRCA1-associated breast cancer
Long-term follow-up of a randomised trial designed to determine the need for irradiation following conservative surgery for the treatment of invasive breast cancer
Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial
Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects
RT-PCR determination of maspin and mammaglobin B in peripheral blood of healthy donors and breast cancer patients
A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients
Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer
Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer
Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma
Analysis of clinical decision-making in multi-disciplinary cancer teams
Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma
Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial
Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patients
‘Blind’ antibiotic treatment targeting Chlamydia is not effective in patients with MALT lymphoma of the ocular adnexa
Characterization of familial Waldenström's macroglobulinemia
Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients
The presentation and survival of patients with non-cutaneous AIDS-associated Kaposi's sarcoma
Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors? A retrospective analysis
Impact of providing booklets about chemotherapy to newly presenting patients with cancer: a randomized controlled trial
Folate intake and squamous-cell carcinoma of the oesophagus in Italian and Swiss men
Unilateral nail changes secondary to adriamycin: the protective effect of brachial plexopathy
Lack of response of cetuximab plus oxaliplatin in advanced colorectal cancer patients resistant to both oxaliplatin and cetuximab plus irinotecan
Catheter-associated thrombosis: thromboprophylaxis for cancer patients who carry factor V Leiden?
Follow-up strategy of germ cell tumour patients
Is high-dose chemotherapy based on carboplatin, a late dose-intensification of a cisplatin-based salvage chemotherapy in germ cell tumour patients?
Bevacizumab plus high-dose ifosfamide, etoposide and carboplatin (HD-ICE) as third-line salvage chemotherapy induced an unexpected dramatic response in highly platinum refractory germ-cell cancer
Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas
Corrigendum